Quinolone Prophylaxis for the Prevention of BK Virus Infection in Kidney Transplantation: A Pilot Study

Inclusion Criteria: * a primary or repeat kidney transplant recipient (deceased or living donor) * age greater or equal to 18 years Exclusion Criteria: * Unable to provide informed consent * Greater than 5 days post-transplantation * BK virus nephropathy with a previous transplant * History of allergic reaction to any quinolone antibiotic * History of quinolone associated tendonitis or tendon rupture * Corrected QT interval prolongation on EKG as defined by Al-Khatib * Concomitant use of medication known to prolong the QT interval such as class IA antiarrhythmic drugs (e.g. quinidine, procainamide, disopyramide), class III antiarrhythmic drugs (e.g. amiodarone, sotalol), azole antifungals (e.g. fluconazole) or macrolide antibiotics (e.g. erythromycin) * Pregnant or breastfeeding as safety of levofloxacin not established * Requires quinolone antibiotic for more than 14 days (e.g. for UTI prophylaxis) * Recipient of a multi-organ transplant (e.g. kidney-pancreas) * Currently enrolled in another interventional trial * Previously enrolled in this study * History of rhabdomyolysis * Significant allergic reaction to ≥ 3 classes of antibiotics as these patients may have no other option other than quinolones for routine infection.